NCT06037317View on ClinicalTrials.gov

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

May 30, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

SY-3505

LTK tyrosine kinase inhibitor

Trial Locations (1)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Shouyao Holdings (Beijing) Co. LTD

OTHER